{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:51:16Z","timestamp":1786985476244,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.brachy.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T02:29:33Z","timestamp":1622600973000},"page":"1053-1061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events of after-loading high dose rate brachytherapy reported to the United States Food and Drug Administration (FDA)"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-4604","authenticated-orcid":false,"given":"Destie","family":"Provenzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Cifter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fischer-Valuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Sarfaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Aghdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ojong-Ntui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-9341","authenticated-orcid":false,"given":"Murray H.","family":"Loew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-2197","authenticated-orcid":false,"given":"Yuan James","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2021.04.005_bib0001","unstructured":"Gerbaulet, A., & Gerbaulet, A. (Eds.). 2002. The GEC ESTRO handbook of brachytherapy."},{"key":"10.1016\/j.brachy.2021.04.005_bib0002","first-page":"2114","article-title":"The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer","volume":"120","author":"Martin","year":"2014","journal-title":"Data Base Cancer"},{"key":"10.1016\/j.brachy.2021.04.005_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","article-title":"Trends in the utilization of brachytherapy in cervical cancer in the United States","volume":"87","author":"Han","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0004","first-page":"555","article-title":"Brachytherapy in the treatment of cervical cancer: A review","volume":"6","author":"Banerjee","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.brachy.2021.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2014.07.017","article-title":"National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: The impact of new technological advancements","volume":"90","author":"Gill","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0006","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijrobp.2019.10.042","article-title":"A Phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer","volume":"106","author":"Albuquerque","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.brachy.2016.12.005","article-title":"Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.","volume":"16","author":"Romano","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.brachy.2018.11.008","article-title":"Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy","volume":"18","author":"Lin","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semradonc.2019.08.003","article-title":"HDR prostate brachytherapy","volume":"30","author":"Crook","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ijrobp.2016.03.037","article-title":"Long-term cancer outcomes from study NRG oncology\/RTOG 9517: A Phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early-stage breast cancer","volume":"95","author":"White","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijrobp.2016.08.050","article-title":"Adverse Events involving radiation oncology medical devices: Comprehensive analysis of US Food and Drug Administration Data, 1991 to 2015","volume":"97","author":"Connor","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.prro.2011.08.004","article-title":"A 2-year review of recent nuclear regulatory commission events: What errors occur in the modern brachytherapy era?","volume":"2","author":"Richardson","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0013","unstructured":"Device Adverse Event Overview. Available at: https:\/\/open.fda.gov\/apis\/device\/event\/. Accessed April 4, 2021"},{"key":"10.1016\/j.brachy.2021.04.005_bib0014","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.brachy.2019.10.006","article-title":"Resident experience in brachytherapy: An analysis of Accreditation Council for Graduate Medical Education case logs for intracavitary and interstitial brachytherapy from 2007 to 2018","volume":"19","author":"Shinde","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2019.03.013","article-title":"Fellowship training programs in radiation oncology: A snapshot from 2005 to 2017","volume":"104","author":"Doke","year":"2019","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.brachy.2012.04.002","article-title":"Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low\/intermediate prostate cancer","volume":"11","author":"Shah","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0017","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.brachy.2020.08.018","article-title":"Development, implementation, and associated challenges of a new HDR brachytherapy program","volume":"19","author":"Scanderbeg","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.04.005_bib0018","doi-asserted-by":"crossref","unstructured":"Romano K.D., Pugh K.J., Trifiletti D.M., et al. Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity. Brachytherapy. 2017;16:378\u2013386. doi: 10.1016\/j.brachy.2016.12.005. Epub 2017 Jan 27. PMID: 28139420.","DOI":"10.1016\/j.brachy.2016.12.005"},{"key":"10.1016\/j.brachy.2021.04.005_bib0019","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.radonc.2017.07.032","article-title":"Patient safety is improved with an incident learning system\u2014Clinical evidence in brachytherapy","volume":"125","author":"Deufel","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ijrobp.2017.02.006","article-title":"Medical device recalls in radiation oncology: Analysis of US Food and Drug Administration Data, 2002-2015","volume":"98","author":"Connor","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0021","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.radonc.2006.05.010","article-title":"Clinical experience with the MammoSite radiation therapy system for brachytherapy of breast cancer: Results from an international phase II trial","volume":"79","author":"Niehoff","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.breast.2006.05.002","article-title":"Early European experience with the MammoSite radiation therapy system for partial breast brachytherapy following breast conservation operation in low-risk breast cancer","volume":"15","author":"Niehoff","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.brachy.2021.04.005_bib0023","first-page":"3021","article-title":"Evaluation of three APBI techniques under NSABP B-39 guidelines","volume":"11","author":"Scanderbeg","year":"2009","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ijrobp.2018.11.012","article-title":"Intensity modulated radiation therapy and image-guided adapted brachytherapy for cervix cancer","volume":"103","author":"Lin","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.04.005_bib0025","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.04.005_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.brachy.2017.09.009","article-title":"Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry","volume":"17","author":"Gabani","year":"2018","journal-title":"Brachytherapy"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:16:23Z","timestamp":1761531383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472121000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1538472121000982"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2021.04.005","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events of after-loading high dose rate brachytherapy reported to the United States Food and Drug Administration (FDA)","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}